Literature DB >> 16412385

Characterization of the two catalytic domains in histone deacetylase 6.

Hua Zou1, Yiqin Wu, Marc Navre, Bi-Ching Sang.   

Abstract

Histone deacetylase 6 (HDAC6) is the only known HDAC with two potentially functional catalytic domains, yet the role towards substrate played by these two domains remains ambiguous. Most studies report HDAC6 activities measured using either immune complexes or in vitro translated products. Here, we characterize the activity of highly purified recombinant HDAC6, mutants with active site histidine mutations in each domain (H216A and H611A), and individual catalytic domains. The deacetylase activities of these proteins, as well as their kinetic parameters, were measured using histone, alpha-tubulin, and fluorogenic acetylated lysine as substrates. Mutant H216A only slightly lowers the catalytic rate. However, mutant H611A decreases the catalytic rate more than 5000-fold. The first domain expressed alone is not catalytically active. In contrast, the second domain shows only a modest decrease in substrate binding and product formation rate. Our results indicate that the in vitro deacetylase activity of HDAC6 resides in the C-terminal second catalytic domain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412385     DOI: 10.1016/j.bbrc.2005.12.144

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  43 in total

1.  Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation.

Authors:  Yuanjing Liu; Lirong Peng; Edward Seto; Suming Huang; Yi Qiu
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

2.  HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.

Authors:  R B Parmigiani; W S Xu; G Venta-Perez; H Erdjument-Bromage; M Yaneva; P Tempst; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-07       Impact factor: 11.205

3.  Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin.

Authors:  David Kaluza; Jens Kroll; Sabine Gesierich; Tso-Pang Yao; Reinier A Boon; Eduard Hergenreider; Marc Tjwa; Lothar Rössig; Edward Seto; Hellmut G Augustin; Andreas M Zeiher; Stefanie Dimmeler; Carmen Urbich
Journal:  EMBO J       Date:  2011-08-16       Impact factor: 11.598

4.  Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.

Authors:  Nicholas J Porter; Florence F Wagner; David W Christianson
Journal:  Biochemistry       Date:  2018-05-18       Impact factor: 3.162

5.  Histone deacetylase 6 associates with ribosomes and regulates de novo protein translation during arsenite stress.

Authors:  Kyle V Kappeler; Jack Zhang; Thai Nho Dinh; Joshua G Strom; Qin M Chen
Journal:  Toxicol Sci       Date:  2012-02-23       Impact factor: 4.849

Review 6.  Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.

Authors:  Jeremy D Osko; David W Christianson
Journal:  Bioorg Med Chem Lett       Date:  2020-02-11       Impact factor: 2.823

Review 7.  Alcohol-induced protein hyperacetylation: mechanisms and consequences.

Authors:  Blythe D Shepard; Pamela L Tuma
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

8.  HDAC6 regulates mutant SOD1 aggregation through two SMIR motifs and tubulin acetylation.

Authors:  Jozsef Gal; Jing Chen; Kelly R Barnett; Liuqing Yang; Erin Brumley; Haining Zhu
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

9.  Inhibition of histone deacetylase 6 restores innate immune cells in the bone marrow in a lethal septic model.

Authors:  Ting Zhao; Yongqing Li; Baoling Liu; Baihong Pan; Xin Cheng; Patrick Georgoff; Hasan B Alam
Journal:  J Trauma Acute Care Surg       Date:  2016-01       Impact factor: 3.313

10.  CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.

Authors:  Sara A Wickström; Katarzyna C Masoumi; Saadi Khochbin; Reinhard Fässler; Ramin Massoumi
Journal:  EMBO J       Date:  2009-11-05       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.